Valuation: Absci Corporation

Market Cap 1.71B 1.47B 1.37B 1.26B 2.37B 164B 2.41B 16.16B 6.34B 82.09B 6.44B 6.3B 271B P/E 2026 *
-12.5x
P/E 2027 * -14.6x
Enterprise Value 1.56B 1.34B 1.24B 1.15B 2.15B 149B 2.19B 14.71B 5.77B 74.71B 5.86B 5.73B 247B EV / Sales 2026 *
406x
EV / Sales 2027 * 89.6x
Free-Float
88.15%
Yield 2026 *
-
Yield 2027 * -
1 day-0.40%
1 week+6.16%
Current month+28.41%
1 month+20.43%
3 months+102.02%
6 months+270.00%
Current year+186.25%
1 week 8.55
Extreme 8.55
10.02
1 month 6.69
Extreme 6.692
10.02
Current year 2.24
Extreme 2.24
12.06
1 year 2.24
Extreme 2.24
12.06
3 years 1.11
Extreme 1.1111
12.06
5 years 1.11
Extreme 1.1111
23.62
10 years 1.11
Extreme 1.1111
31.53
Manager TitleAgeSince
Chief Executive Officer 36 2011-07-31
Director of Finance/CFO 53 2023-08-30
Chief Tech/Sci/R&D Officer - 2025-07-31
Director TitleAgeSince
Director/Board Member 36 2010-12-31
Director/Board Member 59 2020-07-31
Director/Board Member 57 2022-01-06
Date Insider Type Main position Quantity % Market Cap.
8/3/26 Free

Chief Technology Officer

383,000 0.2261%
6/30/26 Buy

Director

12,900 0.0076%
3/2/26 Free

Chief Financial Officer

680,648 0.4526%
Change 5-day change 1-year change 3-year change Capi.($)
+12.88%+6.16%+253.00%+494.64% 1.52B
+2.37%+0.66%+4.21%+22.74% 48.63B
-0.62%+4.43%+488.92%+624.71% 46.3B
+2.09%+4.90%+18.02%+95.21% 41.97B
+3.85%+2.23%+29.47%+16.50% 39.51B
-0.72%-7.79%+17.87%+47.98% 31.75B
+3.04%+0.46%+31.40%+143.62% 16.48B
+4.33%+1.98% - - 16.34B
+1.44%+1.09%+4.93%+31.00% 14B
+3.87%+2.84%+84.74%+45.80% 13.33B
Average +1.38%-1.14%+103.62%+169.13% 26.98B
Weighted average by Cap. +1.57%-0.08%+108.21%+159.23%

Financials

2026 *2027 *
Net sales 3.84M 3.29M 3.06M 2.82M 5.3M 368M 5.39M 36.2M 14.21M 184M 14.42M 14.1M 607M 16.15M 13.83M 12.87M 11.87M 22.29M 1.55B 22.66M 152M 59.75M 773M 60.62M 59.3M 2.55B
Net income -128M -110M -102M -94.16M -177M -12.27B -180M -1.21B -474M -6.13B -481M -471M -20.25B -121M -104M -96.39M -88.86M -167M -11.58B -170M -1.14B -447M -5.79B -454M -444M -19.11B
Net Debt -154M -132M -123M -113M -213M -14.76B -216M -1.45B -571M -7.38B -579M -566M -24.37B -268M -230M -214M -197M -371M -25.71B -377M -2.53B -994M -12.86B -1.01B -986M -42.44B
Logo Absci Corporation
Absci Corporation is a clinical-stage biopharmaceutical company advancing therapeutics with generative design. Its Integrated Drug Creation platform combines artificial intelligence (AI) models with a synthetic biology data engine, enabling the design of therapeutics that address challenging therapeutic targets. Its approach leverages a continuous feedback loop between advanced AI algorithms and wet lab validation. Alongside collaborations with pharmaceutical, biotech, tech, and academic companies, the Company is advancing its own pipeline of AI- designed therapeutics. These include ABS-101, an antibody to treat inflammatory bowel disease (IBD), as well as other indications, and ABS-201, for hair regrowth with the potential to redefine treatment possibilities for androgenetic alopecia, commonly known as male and female pattern baldness. It has four wholly owned, internally developed programs focusing on cytokine biology. Its other pipeline programs include ABS-301 and ABS-501.
Employees
140
Date Price Change Volume
26-08-19 US$9.990 +12.88% 4,491,761
26-08-18 US$8.850 -4.22% 2,482,404
26-08-17 US$9.240 +0.65% 2,145,092
26-08-14 US$9.180 -2.96% 2,231,297
26-08-13 US$9.460 -0.42% 2,553,150
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
10
Last Close Price
9.990USD
Average target price
13.89USD
Spread / Average Target
+39.03%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. ABSI Stock